7L56
| Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-43 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Fab 2-43 variable domain heavy chain, ... | Authors: | Rapp, M, Shapiro, L. | Deposit date: | 2020-12-21 | Release date: | 2021-04-14 | Last modified: | 2023-04-05 | Method: | ELECTRON MICROSCOPY (3.6 Å) | Cite: | Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class. Cell Rep, 35, 2021
|
|
7L58
| Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab H4 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Fab H4 variable domain heavy chain, ... | Authors: | Rapp, M, Shapiro, L. | Deposit date: | 2020-12-21 | Release date: | 2021-04-14 | Last modified: | 2024-10-23 | Method: | ELECTRON MICROSCOPY (5.07 Å) | Cite: | Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class. Cell Rep, 35, 2021
|
|
7LSS
| Cryo-EM structure of the SARS-CoV-2 spike glycoprotein bound to Fab 2-7 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Fab 2-7 variable heavy chain, ... | Authors: | Rapp, M, Shapiro, L. | Deposit date: | 2021-02-18 | Release date: | 2021-03-17 | Last modified: | 2024-10-16 | Method: | ELECTRON MICROSCOPY (3.72 Å) | Cite: | Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies. Structure, 29, 2021
|
|
7LS9
| |
7N5H
| Cryo-EM structure of broadly neutralizing antibody 2-36 in complex with prefusion SARS-CoV-2 spike glycoprotein | Descriptor: | 2-36 Fab heavy chain, 2-36 Fab light chain, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... | Authors: | Casner, R.G, Cerutti, G, Shapiro, L. | Deposit date: | 2021-06-05 | Release date: | 2021-11-03 | Last modified: | 2024-10-16 | Method: | ELECTRON MICROSCOPY (3.24 Å) | Cite: | A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses. Emerg Microbes Infect, 11, 2022
|
|
7LQV
| Cryo-EM structure of NTD-directed neutralizing antibody 4-8 Fab in complex with SARS-CoV-2 S2P spike | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 4-8 Heavy Chain, 4-8 Light chain, ... | Authors: | Gorman, J, Rapp, M, Kwong, P.D, Shapiro, L. | Deposit date: | 2021-02-15 | Release date: | 2021-03-24 | Last modified: | 2024-10-16 | Method: | ELECTRON MICROSCOPY (3.25 Å) | Cite: | Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite Cell Host Microbe, 2021
|
|
7LQW
| Cryo-EM structure of NTD-directed neutralizing antibody 2-17 Fab in complex with SARS-CoV-2 S2P spike | Descriptor: | 2-17 Heavy Chain, 2-17 Light Chain, 2-acetamido-2-deoxy-beta-D-glucopyranose, ... | Authors: | Gorman, J, Rapp, M, Kwong, P.D, Shapiro, L. | Deposit date: | 2021-02-15 | Release date: | 2021-03-24 | Last modified: | 2021-05-26 | Method: | ELECTRON MICROSCOPY (4.47 Å) | Cite: | Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Cell Host Microbe, 29, 2021
|
|
7MY2
| |
7MY3
| |
7MXP
| Cryo-EM structure of NTD-directed neutralizing antibody LP5 Fab in complex with SARS-CoV-2 S2P spike | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[2-acetamido-2-deoxy-beta-D-glucopyranose-(1-2)][beta-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, ... | Authors: | Reddem, E.R, Casner, R.G, Shapiro, L. | Deposit date: | 2021-05-19 | Release date: | 2022-05-25 | Last modified: | 2024-10-30 | Method: | ELECTRON MICROSCOPY (4.46 Å) | Cite: | Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS-CoV-2. Aiche J, 67, 2021
|
|